Effects of 2 Initial Standard Antiretroviral Combinations Therapies on Lipid Metabolism in ARV-Naive HIV-Infected Subjects.

Trial Profile

Effects of 2 Initial Standard Antiretroviral Combinations Therapies on Lipid Metabolism in ARV-Naive HIV-Infected Subjects.

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 13 Aug 2015

At a glance

  • Drugs Efavirenz (Primary) ; Emtricitabine/tenofovir disoproxil fumarate (Primary) ; Lopinavir/ritonavir (Primary)
  • Indications HIV-1 infections
  • Focus Adverse reactions; Pharmacogenomic
  • Most Recent Events

    • 06 Mar 2013 Results of the adipose tissue sub-study presented at the 20th Conference on Retroviruses and Opportunistic Infections.
    • 21 Feb 2013 Planned end date changed from 1 Mar 2011 to 1 Jul 2013 as reported by ClinicalTrials.gov.
    • 02 Apr 2010 Planned end date changed from 1 Jul 2010 to 1 Mar 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top